GLPwatch
Papers (10373)
Page 63 of 173, ranked by citation count.
- Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.
- The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date.
- Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
- Glucagon-like peptide-1 receptor agonists and kidney outcomes.
- Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.
- Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.
- Synergistic effect of glucagon-like peptide-1 analogue liraglutide and ZnO on the antibacterial, hemostatic, and wound healing properties of nanofibrous dressings.
- Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice.
- Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.
- The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials.
- Inhibition of the MAP3 kinase Tpl2 protects rodent and human β-cells from apoptosis and dysfunction induced by cytokines and enhances anti-inflammatory actions of exendin-4.
- Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
- EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
- Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.
- Semaglutide treatment of hypothalamic obesity - a real-life data study.
- Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
- Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.
- Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.
- Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
- Newer antidiabetic drugs and calorie restriction mimicry.
- An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists.
- Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model.
- Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.
- A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model.
- Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
- New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies.
- Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
- Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.
- Liraglutide treatment improves endothelial function in the Ldlr-/- mouse model of atherosclerosis and affects genes involved in vascular remodelling and inflammation.
- Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users.
- Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.
- Insufficient sleep predicts poor weight loss maintenance after 1 year.
- Managing Adverse Effects of Incretin-Based Medications for Obesity.
- GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells.
- Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetes retinopathy.
- Lixisenatide: a review of its use in patients with type 2 diabetes mellitus.
- Glucagon-like peptide-1 receptor agonist exendin 4 ameliorates diabetes-associated vascular calcification by regulating mitophagy through the AMPK signaling pathway.
- Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
- Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice.
- Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
- Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
- Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
- Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.
- A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.
- Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus.
- Efficacy of Intragastric Balloon versus Liraglutide as Bridge to Surgery in Super-Obese Patients.
- Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.
- GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats.
- Stability of exenatide in poly(D,L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer.
- The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.
- Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.
- Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate.
- Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis.
- Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.
- Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.
- Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
- Targeted ion parking for the quantitation of biotherapeutic proteins: concepts and preliminary data.
- Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.
- A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.